Company profile: Humanigen
1.1 - Company Overview
Company description
- Provider of biopharmaceutical development focused on human antibody therapeutics.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Humanigen
HilleVax
HQ: United States
Website
- Description: Provider of novel vaccine development and commercialization, focused on HIL-214, a bivalent GI.1/GII.4 virus-like particle (VLP) vaccine candidate in development to prevent moderate-to-severe acute gastroenteritis caused by norovirus infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HilleVax company profile →
PhagoMed
HQ: Austria
Website
- Description: Provider of a biotech platform for developing drugs and therapies, focusing on human therapeutic applications of phages and phage-derived proteins to address urinary tract infections and bacterial vaginosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhagoMed company profile →
Infant Bacterial Therapeutics
HQ: Sweden
Website
- Description: Provider of clinical-stage pharmaceutical drug development focused on influencing the infant microbiome to prevent or treat rare diseases in infants. Developing IBP-9414 to prevent NEC in premature infants; IBP-9414 contains the active substance Lactobacillus reuteri, a human bacterial strain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Infant Bacterial Therapeutics company profile →
IQuum
HQ: United States
Website
- Description: Provider of molecular diagnostics and biological sample technology, developing an early-stage platform to improve extraction of information from biological samples and deliver recent advances in genomics and biotechnology to healthcare and daily life; founded in 1998 in the Boston metropolitan area.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IQuum company profile →
Nabriva Therapeutics
HQ: Austria
Website
- Description: Provider of innovative anti-infective agents to treat serious infections, including XENLETA (lefamulin) for adult CABP, IV and oral, FDA-approved; CONTEPO (fosfomycin) IV for complicated urinary tract infections, including acute pyelonephritis, active against multi-drug resistant strains; and BC-7013, a topical pleuromutilin candidate for Gram-positive infections, including uncomplicated skin and skin structure infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nabriva Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Humanigen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Humanigen
2.2 - Growth funds investing in similar companies to Humanigen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Humanigen
4.2 - Public trading comparable groups for Humanigen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →